Unknown statusObservationalLast updated Jan 26, 2023

Preclinical Research for Personalized TCR-T Therapy for Head and Neck Cancer

Overview

ClinicalTrials.gov ID: NCT05697926
Lead Sponsor: Eye & ENT Hospital of Fudan UniversityOTHER
Brief Summary: This study will obtain tumor samples from patients with head and neck cancers and aims to develop personalized TCR-T therapy for head and neck cancer by determining the reactive TCR clone sequences in head and neck cancer.
Study Type: Observational

Status

Overall Status: Unknown status
Start Date: Mar 1, 2023Estimated
Primary Completion Date: Dec 31, 2025Estimated
Completion Date: Jun 30, 2026Estimated

Study Record Dates

First Submitted: Jan 1, 2023
First Submitted that Met QC Criteria: Jan 15, 2023
First Posted: Jan 26, 2023Actual
Last Update Submitted that Met QC Criteria: Jan 15, 2023
Last Update Posted: Jan 26, 2023Actual
Last Verified: Jan 2023

NCT06804850Withdrawn

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

NCT06005324Recruiting

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

NCT07040956Completed

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

NCT02881918Unknown status

Anti-tumor Specific Immune Response in Head and Neck Cancers

NCT01818323Unknown status

Phase I Trial: T4 Immunotherapy of Head and Neck Cancer

NCT03047811Unknown status

The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors